Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 82.92% is 96% above its 5-year average of 42.26%, near the high end of its 5-year range (0.00%–87.50%).
1.42% below its 12-month average of 84.11%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 79.68%.
GROSS MARGIN
82.92%
GROSS MARGIN AVG TTM
84.11%
GROSS MARGIN AVG 3Y
83.92%
GROSS MARGIN AVG 5Y
42.26%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.42%
CURRENT VS 3Y AVG
-1.19%
CURRENT VS 5Y AVG
+96.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.39%
vs the sector median at left
Phathom Pharmaceuticals, Inc.
Market Cap
$548.51M
Gross Margin
82.92%
TTM Avg
84.11%
3Y Avg
83.92%
5Y Avg
42.26%
Market Cap
$557.32M
Gross Margin
98.63%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$538.01M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
33.33%
Market Cap
$533.04M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$531.98M
Gross Margin
87.05%
TTM Avg
84.77%
3Y Avg
78.39%
5Y Avg
75.97%
Market Cap
$531.52M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$529.58M
Gross Margin
-195.10%
TTM Avg
-90.32%
3Y Avg
-3207.95%
5Y Avg
-2168.95%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $548.51M | 82.92% | 84.11% | 83.92% | 42.26% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | 98.63% | 100.00% | 100.00% | 100.00% |
| ProKidney Corp. (PROK)vs › | $538.01M | 100.00% | 100.00% | 50.00% | 33.33% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 87.05% | 84.77% | 78.39% | 75.97% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | -195.10% | -90.32% | -3207.95% | -2168.95% |
| CorMedix Inc. (CRMD)vs › | $571.13M | 82.78% | 90.56% | 68.85% | 51.96% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
82.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 79.68% |
| 2026-03-31 | 79.42% |
| 2025-12-31 | 86.72% |
| 2025-09-30 | 87.50% |
| 2025-06-30 | 87.25% |
| 2025-03-31 | 86.94% |
| 2024-12-31 | 87.14% |
| 2024-09-30 | 85.59% |
| 2024-06-30 | 81.21% |
| 2024-03-31 | 77.72% |
| 2023-12-31 | 48.39% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
